ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
All resolutions were approved. 35% of the issued shares represented. MADRID, Spain and BOSTON, June…
News
ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
All resolutions were approved. 35% of the issued shares represented. MADRID, Spain and BOSTON, June…
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
Immutep Completes A$80 Million Capital Raise
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
Immutep Completes A$80 Million Capital Raise
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
Joint Venture (JV) combines CENTOGENE’s global leadership in multiomics with local insight of Lifera, a…
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
Joint Venture (JV) combines CENTOGENE’s global leadership in multiomics with local insight of Lifera, a…
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP),…
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP),…
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated…
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated…
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features,…
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features,…
First Wave BioPharma Strengthens Intellectual Property Estate
USPTO and WIPO both publish two adrulipase patent applications for composition of matter and methods…
First Wave BioPharma Strengthens Intellectual Property Estate
USPTO and WIPO both publish two adrulipase patent applications for composition of matter and methods…
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with…
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with…